FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387392732> ?p ?o ?g. }

• W4387392732 abstract "Deucravacitinib, a newly approved oral medication for the treatment of patients with moderate to severe plaque psoriasis, demonstrated efficacy versus apremilast and placebo in two phase 3 randomized controlled trials (RCTs). A systematic review and network meta-analysis (NMA) indirectly compared deucravacitinib with other relevant systemic biologic/nonbiologic treatments.Online databases were searched for RCTs published through October 2021. Eligible studies were head-to-head comparisons between systemic therapies and/or placebo reporting 50%, 75%, 90%, or 100% improvement in Psoriasis Area and Severity Index (PASI) from baseline in adults with moderate to severe plaque psoriasis. Comparisons included tumor necrosis factor inhibitors, interleukin (IL)-17, IL-23, and IL 12/23 inhibitors, and systemic nonbiologics. A multinomial Bayesian NMA was used to derive estimates of the relative efficacy of deucravacitinib and other systemic therapies. Response probabilities for each treatment and corresponding 95% credible intervals (CrIs) for achieving a PASI response were calculated over short-, mid-, and long-term follow-up (weeks 10-16, 24-28, and 44-60).The NMA included 47 RCTs. Deucravacitinib showed the highest PASI 75 response rates among nonbiologic systemic therapies across time points. Deucravacitinib PASI 75 response rate (95% CrI) over short-term follow-up was 54.1% (46.5-61.6), within the range of first-generation biologics (etanercept, 39.7% [31.6-48.3]; infliximab, 79.0% [74.0-83.5]). At mid-term follow-up, deucravacitinib PASI 75 increased to 63.3% (58.0-68.4). At long-term follow-up, deucravacitinib PASI 75 was 65.9% (58.0-73.4), comparable to first-generation biologics adalimumab (62.8%; 55.3-69.6) and ustekinumab (68.0%; 64.6-71.5).Patients receiving deucravacitinib were more likely to achieve PASI 75 response versus apremilast and methotrexate across all time points. The long-term PASI 75 response rate for deucravacitinib was similar to those of adalimumab and ustekinumab. The approval of deucravacitinib offers patients the choice of an oral therapy with long-term efficacy similar to that of some biologics." @default.
• W4387392732 created "2023-10-07" @default.
• W4387392732 creator A5013763025 @default.
• W4387392732 creator A5027096668 @default.
• W4387392732 creator A5030318108 @default.
• W4387392732 creator A5033903141 @default.
• W4387392732 creator A5054149999 @default.
• W4387392732 creator A5075009838 @default.
• W4387392732 creator A5077495991 @default.
• W4387392732 creator A5079720886 @default.
• W4387392732 creator A5081357330 @default.
• W4387392732 creator A5082315246 @default.
• W4387392732 creator A5085332260 @default.
• W4387392732 date "2023-10-06" @default.
• W4387392732 modified "2023-10-09" @default.
• W4387392732 title "Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis" @default.
• W4387392732 cites W1541270304 @default.
• W4387392732 cites W1541913191 @default.
• W4387392732 cites W1572018981 @default.
• W4387392732 cites W1587070562 @default.
• W4387392732 cites W1751814457 @default.
• W4387392732 cites W1845936179 @default.
• W4387392732 cites W1909750378 @default.
• W4387392732 cites W1919283206 @default.
• W4387392732 cites W1957267795 @default.
• W4387392732 cites W1965032245 @default.
• W4387392732 cites W1973354423 @default.
• W4387392732 cites W1975463338 @default.
• W4387392732 cites W1996773947 @default.
• W4387392732 cites W2005176759 @default.
• W4387392732 cites W2008716526 @default.
• W4387392732 cites W2013361256 @default.
• W4387392732 cites W2030348118 @default.
• W4387392732 cites W2052065030 @default.
• W4387392732 cites W2063627867 @default.
• W4387392732 cites W2074205207 @default.
• W4387392732 cites W2080390872 @default.
• W4387392732 cites W2086861262 @default.
• W4387392732 cites W2088155036 @default.
• W4387392732 cites W2091442391 @default.
• W4387392732 cites W2099687194 @default.
• W4387392732 cites W2103750969 @default.
• W4387392732 cites W2116956799 @default.
• W4387392732 cites W2127834887 @default.
• W4387392732 cites W2131727392 @default.
• W4387392732 cites W2138647255 @default.
• W4387392732 cites W2139369419 @default.
• W4387392732 cites W2146843653 @default.
• W4387392732 cites W2149566497 @default.
• W4387392732 cites W2163232748 @default.
• W4387392732 cites W2164533070 @default.
• W4387392732 cites W2168911501 @default.
• W4387392732 cites W2171889601 @default.
• W4387392732 cites W2247689163 @default.
• W4387392732 cites W2276035339 @default.
• W4387392732 cites W2326643498 @default.
• W4387392732 cites W2412745703 @default.
• W4387392732 cites W2418506270 @default.
• W4387392732 cites W2470133599 @default.
• W4387392732 cites W2506995112 @default.
• W4387392732 cites W2510028480 @default.
• W4387392732 cites W2512942811 @default.
• W4387392732 cites W2532238474 @default.
• W4387392732 cites W2535494101 @default.
• W4387392732 cites W2562079198 @default.
• W4387392732 cites W2565351134 @default.
• W4387392732 cites W2570140560 @default.
• W4387392732 cites W2570141807 @default.
• W4387392732 cites W2605232103 @default.
• W4387392732 cites W2620306249 @default.
• W4387392732 cites W2623888527 @default.
• W4387392732 cites W2753520953 @default.
• W4387392732 cites W2781078917 @default.
• W4387392732 cites W2785965739 @default.
• W4387392732 cites W2794845062 @default.
• W4387392732 cites W2797132528 @default.
• W4387392732 cites W2797238574 @default.
• W4387392732 cites W2804753859 @default.
• W4387392732 cites W2808102618 @default.
• W4387392732 cites W2886066930 @default.
• W4387392732 cites W2887412253 @default.
• W4387392732 cites W2895363302 @default.
• W4387392732 cites W2895775669 @default.
• W4387392732 cites W2896987528 @default.
• W4387392732 cites W2902932442 @default.
• W4387392732 cites W2912787118 @default.
• W4387392732 cites W2924267060 @default.
• W4387392732 cites W2946192037 @default.
• W4387392732 cites W2955205003 @default.
• W4387392732 cites W2955490990 @default.
• W4387392732 cites W2963660305 @default.
• W4387392732 cites W2965085195 @default.
• W4387392732 cites W2967449819 @default.
• W4387392732 cites W2970684805 @default.
• W4387392732 cites W2997875868 @default.
• W4387392732 cites W3000497236 @default.
• W4387392732 cites W3005392748 @default.
• W4387392732 cites W3008728180 @default.
• W4387392732 cites W3014609838 @default.
• W4387392732 cites W3037060742 @default.

• next